What is the Gemigliptin?

Gemigliptin is , while it's Molecular Formula is C 18 H 19 F 8 N 5 O 2 . Gemigliptin Hydrochloride is used in biological studies as a novel dipeptidyl peptidase IV (DPP-IV) inhibitors and potential antidiabetic drug.

What is the CAS number for Gemigliptin?

The CAS number of Gemigliptin is 911637-19-9.

What is Gemigliptin (911637-19-9) used for?

Gemigliptin is a prolyl-specific dipeptidyl aminopeptidase IV(DPP IV, DPP-4, CD26) inhibitor approved for the treatment of type2 diabetes mellitus by the Korean Food and Drug Administration in2012. Gemigliptin was discovered and developed by LG LifeSciences and is now the sixth DPP-4 inhibitor approved for thetreatment of type 2 diabetes. At the time this review was prepared,there were no publications describing the discovery strategyand preclinical data that led to the advancement of gemigliptin to the clinic.

Product Class

911637-19-9

Product Name：Gemigliptin Tartarate
Molecular Formula：C₂₂H₂₅F₈N₅O₈
Purity：99%
Molecular Weight：489.368

Inquiry

Product Details:

CasNo： 911637-19-9

Molecular Formula： C₂₂H₂₅F₈N₅O₈

Chinese Factory Supply Gemigliptin Tartarate,Sale 911637-19-9 Efficient Transportation

Molecular Formula:C₁₈H₁₉F₈N₅O₂
Molecular Weight:489.368
Boiling Point:539.1±50.0 °C(Predicted)
PKA:7.33±0.10(Predicted)
Density:1.54±0.1 g/cm3(Predicted)

Gemigliptin Tartarate(Cas 911637-19-9) Usage

Description

Gemigliptin tartrate is a potent, selective, reversible, and competitive inhibitor of dipeptidyl peptidase-4 (DPP-4). It is soluble in organic solvents such as DMSO (dimethyl sulfoxide) and dimethyl formamide. This medication is often used in the form of gemigliptin (LC15-0444) tartrate sesquihydrate, which was approved by the Korean Food and Drug Administration (KFDA) in June 2012.

Uses

Gemigliptin tartrate is indicated for the management of hyperglycemia in adults diagnosed with type 2 diabetes mellitus. It is typically prescribed alongside diet and exercise regimens to improve blood sugar control. Gemigliptin works by inhibiting the activity of DPP-4, an enzyme responsible for the breakdown of incretin hormones, which regulate insulin secretion and blood glucose levels. By blocking DPP-4, gemigliptin increases the concentration of active incretin hormones, leading to enhanced insulin release from the pancreas and reduced glucagon secretion, thereby lowering blood sugar levels.

911637-19-9 Relevant articles

Quantitative analysis of gemigliptin tartrate sesquihydrate by 19F quantitative NMR (19F-qNMR)

LIU, Yang; WEI, Ning-yi; ZHANG, Qi; LI, Xiao-dong; HE, Lan; YANG, Hua-xin

Chinese Journal of Pharmaceutical Analysis, Volume 34, Number 7, 2014, pp. 1197-1199(3)

A variety of internal standards can be used in19 F-qNMR,and their spectrums are easy to characterize.The established 19 F-qNMR method is precise and rapid for determination of gemigliptin tartrate sesquihydrate.

Gemigliptin: Newer Promising Gliptin for Type 2 Diabetes Mellitus

M Gutch，A Joshi，S Kumar，A Agarwal，SM Razi

indian journal of endocrinology & metabolism 2017/11/01

The dipeptidyl peptidase-4 (DPP-4) inhibitors have facilitated the management of type 2 diabetes mellitus (T2DM) owing to their superior efficacy and safety with low incidence of adverse effects. Gemigliptin is a new member of this family of drugs, and studies have revealed certain advantages of gemigliptin use compared to its previous congeners.

911637-19-9 Process route

: 911637-19-9
Gemigliptin

Conditions

Conditions	Yield
	56%

Relevant Products

Pralsetinib
CAS：2097132-94-8
4-Fluoro-2-methoxy-5-nitroaniline
CAS：1075705-01-9
Irinotecan Hcl
CAS：100286-90-6